Ketotifen-13C-d3 |
Katalog-Nr.GC47529
One-Click Copy Product Info
|
A neuropeptide with diverse biological activities
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2748522-40-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ketotifen-13C-d3 is intended for use as an internal standard for the quantification of ketotifen by GC- or LC-MS. Ketotifen is a histamine H1 receptor antagonist (Ki = 1.3 nM) and mast cell stabilizer.1,2 It is selective for H1 receptors over H2 and H3 receptors (Kis = 987 and 2,500 nM, respectively).1 Ketotifen (50 and 100 μM) inhibits degranulation of rat peritoneal mast cells induced by compound 48/80 .2 It inhibits the passive cutaneous anaphylaxis (PCA) reaction in rats by 54.6% when administered orally at a dose of 20 mg/kg.3 Ketotifen (30 mg/kg) inhibits the quick phase airway response in a rat ovalbumin-induced immediate airway response model.4 Formulations containing ketotifen have been used in the treatment of itching associated with allergic conjunctivitis.
1.Sharif, N.A., Xu, S.X., and Yanni, J.M.Olopatadine (AL-4943A): Ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitisJ. Ocul. Pharmacol. Ther.12(4)401-407(1996) 2.Baba, A., Tachi, M., Ejima, Y., et al.Anti-allergic drugs tranilast and ketotifen dose-dependently exert mast cell-stabilizing propertiesCell Physiol. Biochem.38(1)15-27(2016) 3.Nishikawa, Y., Shindo, T., Ishi, K., et al.Acrylamide derivatives as antiallergic agents. III. Synthesis and structure-activity relationships of N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]- and N-[4-(4-diphenylmethylene-1-piperidyl)butyl]-3-heteroarylacry lamidesChem. Pharm. Bull. (Tokyo)37(3)684-687(1989) 4.Miyagawa, N., Iwasaki, H., Kato, T., et al.Two pharmacological phases in antigen-induced immediate airway response in ratsBiol. Pharm. Bull.32(12)2260-2264(2008)
| Cas No. | 2748522-40-7 | SDF | |
| Canonical SMILES | O=C1C2=C(C=CS2)/C(C3=CC=CC=C3C1)=C4CCN([13C]([2H])([2H])[2H])CC/4 | ||
| Formula | C18[13C]H16D3NOS | M.Wt | 313.4 |
| Löslichkeit | Acetonitrile: soluble,DMF: soluble,DMSO: soluble,Methanol: soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1908 mL | 15.9541 mL | 31.9081 mL |
| 5 mM | 638.2 μL | 3.1908 mL | 6.3816 mL |
| 10 mM | 319.1 μL | 1.5954 mL | 3.1908 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)